## Pr Denis Angoulvant

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7558414/publications.pdf

Version: 2024-02-01

170 papers

11,282 citations

36 h-index 30922 102 g-index

179 all docs

179 docs citations

179 times ranked

14676 citing authors

#	Article	IF	CITATIONS
1	Regadenoson versus dipyridamole: Evaluation of stress myocardial blood flow response on a CZT-SPECT camera. Journal of Nuclear Cardiology, 2022, 29, 113-122.	2.1	13
2	Lipid goal achievements after acute myocardial infarction: the gap between real-life and ESC 2019 guidelines. European Journal of Preventive Cardiology, 2022, 29, e65-e67.	1.8	2
3	How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and immunomodulators. Panminerva Medica, 2022, 64, .	0.8	4
4	Deleterious synergistic effects of acute heart failure and diabetes mellitus in patients with acute coronary syndrome: Data from the FAST-MI Registries. Archives of Cardiovascular Diseases, 2022, , .	1.6	0
5	Indirect Transfer to Catheterization Laboratory for ST Elevation Myocardial Infarction Is Associated With Mortality Independent of System Delays: Insights From the France-PCI Registry. Frontiers in Cardiovascular Medicine, 2022, 9, 793067.	2.4	1
6	P2x4 receptor promotes mammary cancer progression by sustaining autophagy and associated mesenchymal transition. Oncogene, 2022, 41, 2920-2931.	5.9	15
7	Does the influenza A vaccine have a direct atheroprotective effect?. Archives of Cardiovascular Diseases, 2022, , .	1.6	3
8	Outcomes in patients with acute myocardial infarction and new atrial fibrillation: a nationwide analysis. Clinical Research in Cardiology, 2021, 110, 1431-1438.	3.3	15
9	P2Y11 Agonism Prevents Hypoxia/Reoxygenation- and Angiotensin II-Induced Vascular Dysfunction and Intimal Hyperplasia Development. International Journal of Molecular Sciences, 2021, 22, 855.	4.1	5
10	Sex, age, type of diabetes and incidence of atrial fibrillation in patients with diabetes mellitus: a nationwide analysis. Cardiovascular Diabetology, 2021, 20, 24.	6.8	19
11	Timing of Coronary Revascularization and Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2021, 14, 484-486.	2.9	2
12	Colchicine for Left Ventricular Infarct Size Reduction in Acute Myocardial Infarction: A Phase II, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Protocol – The COVERT-MI Study. Cardiology, 2021, 146, 151-160.	1.4	12
13	INCREASED EXPOSURE TO X-RAYS DURING CORONARY ANGIOGRAPHY AND PERCUTANEOUS CORONARY INTERVENTIONS ASSOCIATED WITH FRACTIONAL FLOW RESERVE MEASUREMENT AND ENDOCORONARY IMAGING TECHNIQUES. Radiation Protection Dosimetry, 2021, 194, 18-26.	0.8	O
14	Risk Scores in ST-Segment Elevation Myocardial Infarction Patients with Refractory Cardiogenic Shock and Veno-Arterial Extracorporeal Membrane Oxygenation. Journal of Clinical Medicine, 2021, 10, 956.	2.4	5
15	NSTE-ACS ESC Guidelines Recommend Prasugrel as the Preferred P2Y12 Inhibitor: A Contrarian View. American Journal of Cardiovascular Drugs, 2021, 21, 483-486.	2.2	3
16	The ICâ€D score for predicting prophylactic cardioverterâ€defibrillator implantation following acute myocardial infarction. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 973-979.	1.2	0
17	ST-segment elevation myocardial infarction: Management and association with prognosis during the COVID-19 pandemic in France. Archives of Cardiovascular Diseases, 2021, 114, 340-351.	1.6	17
18	The Defibrillation Conundrum: New Insights into the Mechanisms of Shock-Related Myocardial Injury Sustained from a Life-Saving Therapy. International Journal of Molecular Sciences, 2021, 22, 5003.	4.1	8

#	Article	lF	Citations
19	Myocardial Flow Reserve Measurement During CZT-SPECT Perfusion Imaging for Coronary Artery Disease Screening: Correlation With Clinical Findings and Invasive Coronary Angiography—The CFR-OR Study. Frontiers in Medicine, 2021, 8, 691893.	2.6	6
20	Cardiovascular Adverse Events With Intravitreal Anti–Vascular Endothelial Growth Factor Drugs. JAMA Ophthalmology, 2021, 139, 610.	2.5	23
21	The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia. JACC: Cardiovascular Imaging, 2021, 14, 2414-2424.	<b>5.</b> 3	44
22	Glucose-lowering drug use and new-onset atrial fibrillation in patients with diabetes mellitus. Diabetologia, 2021, 64, 2602-2605.	6.3	13
23	Compared Outcomes of ST-Segmenta Elevation Myocardial Infarction Patients With Multivessel Disease Treated With Primary Percutaneous Coronary Intervention and Preserved Fractional Flow Reserve of Nonculprit Lesions Treated Conservatively and of Those With Low Fractional Flow Reserve Managed Invasively: Insights From the FLOWER-MI Trial. Circulation: Cardiovascular Interventions,	3.9	20
24	Outcomes in patients with acute myocardial infarction and history of illicit drug use: a French nationwide analysis. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 1027-1037.	1.0	6
25	Metabolically healthy obesity and cardiovascular events: A nationwide cohort study. Diabetes, Obesity and Metabolism, 2021, 23, 2492-2501.	4.4	25
26	Impact of gender on relative rates of cardiovascular events in patients with diabetes. Diabetes and Metabolism, 2021, 47, 101226.	2.9	10
27	Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction. Circulation, 2021, 144, 859-869.	1.6	74
28	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet, The, 2021, 398, 1713-1725.	13.7	142
29	Plasma and genetic determinants of soluble TREM-1 and major adverse cardiovascular events in a prospective cohort of acute myocardial infarction patients. Results from the FAST-MI 2010 study. International Journal of Cardiology, 2021, 344, 213-219.	1.7	3
30	It's never too early to beat your low-density lipoprotein cholesterol. Archives of Cardiovascular Diseases, 2021, 114, 1-3.	1.6	1
31	Association Between Mortality and Anti–Vascular Endothelial Growth Factor Treatment in Patients With Age-Related Macular Degeneration—Reply. JAMA Ophthalmology, 2021, 139, 1247.	2.5	1
32	Fractional Flow Reserve to Guide Treatment of Patients With Multivessel Coronary Artery Disease. Journal of the American College of Cardiology, 2021, 78, 1875-1885.	2.8	51
33	Life-threatening arrhythmias in anterior ST-segment elevation myocardial infarction patients treated by percutaneous coronary intervention: adverse impact of morphine. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 427-436.	1.0	2
34	Combining flow and reserve measurement during myocardial perfusion imaging: A new era for myocardial perfusion scintigraphy?. Archives of Cardiovascular Diseases, 2021, 114, 818-827.	1.6	4
35	Control of Low-Density Lipoprotein Cholesterol in Secondary Prevention of Coronary Artery Disease in Real-Life Practice: The DAUSSET Study in French Cardiologists. Journal of Clinical Medicine, 2021, 10, 5938.	2.4	3
36	Proposal for a standardized discharge letter after hospital stay for acute myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 788-801.	1.0	7

#	Article	IF	CITATIONS
37	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal, 2020, 41, 543-603.	2.2	2,426
38	Does helicopter transport delay prehospital transfer for STEMI patients in rural areas? Findings from the CRAC France PCI registry. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 958-965.	1.0	11
39	Specific impact of past and new major cardiovascular events on acute kidney injury and end-stage renal disease risks in diabetes: a dynamic view. CKJ: Clinical Kidney Journal, 2020, 13, 17-23.	2.9	5
40	Patient care pathways in acute heart failure and their impact on in-hospital mortality, a French national prospective survey. IJC Heart and Vasculature, 2020, 26, 100448.	1.1	7
41	SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia. Atherosclerosis, 2020, 306, 41-49.	0.8	30
42	Renal arteriography with endovascular ultrasound for the management of renal infarction patients. BMC Nephrology, 2020, 21, 273.	1.8	5
43	Acute pathophysiological myocardial changes following intra-cardiac electrical shocks using a proteomic approach in a sheep model. Scientific Reports, 2020, 10, 20252.	3.3	5
44	Hospital admissions for acute myocardial infarction before and after lockdown according to regional prevalence of COVID-19 and patient profile in France: a registry study. Lancet Public Health, The, 2020, 5, e536-e542.	10.0	169
45	Kinetic modelling of myocardial necrosis biomarkers offers an easier, reliable and more acceptable assessment of infarct size. Scientific Reports, 2020, 10, 13597.	3.3	3
46	Incidence, delays, and outcomes of STEMI during COVIDâ€19 outbreak: Analysis from the France PCI registry. Journal of the American College of Emergency Physicians Open, 2020, 1, 1168-1176.	0.7	23
47	The interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 394-404.	3.0	16
48	Long-term outcomes after acute myocardial infarction in patients with familial hypercholesterolemia: The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction program. Journal of Clinical Lipidology, 2020, 14, 352-360.e6.	1.5	13
49	Influenza vaccination as a novel means of preventing coronary heart disease: Effectiveness in older adults. Vaccine, 2020, 38, 4944-4955.	3.8	20
50	Futility Risk Model for Predicting Outcome After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2020, 130, 100-107.	1.6	16
51	Modulation of P2Y11-related purinergic signaling in inflammation and cardio-metabolic diseases. European Journal of Pharmacology, 2020, 876, 173060.	3.5	9
52	Prognosis of Type 2 Myocardial Infarction Patients Implanted With a Prophylactic Defibrillator (from) Tj ETQq0 0	0 rgBT /O	verlock 10 Tf
53	Lipoprotein(a), the rediscovered risk factor, or how to get "back to the future― Archives of Cardiovascular Diseases, 2020, 113, 147-151.	1.6	2
54	Abstract 14715: Diabetes and Relative Rates of Cardiovascular Events in Women Compared With Men. Circulation, 2020, 142, .	1.6	0

#	Article	IF	CITATIONS
55	Performing diagnostic coronary angiography to evaluate high-risk cardiac donors: A French nationwide cohort study. International Journal of Cardiology, 2019, 277, 71-78.	1.7	5
56	Stimulation of P2Y11 receptor protects human cardiomyocytes against Hypoxia/Reoxygenation injury and involves PKCl $\mu$ signaling pathway. Scientific Reports, 2019, 9, 11613.	3.3	14
57	Effects of remote ischemic conditioning on kidney injury in at-risk patients undergoing elective coronary angiography (PREPARE study): a multicenter, randomized clinical trial. Scientific Reports, 2019, 9, 11985.	3.3	8
58	Evaluation of the efficacy of a self-training programme in focus cardiac ultrasound with simulator. Archives of Cardiovascular Diseases, 2019, 112, 576-584.	1.6	12
59	A Look Beyond Statins and Ezetimibe: a Review of Other Lipid-Lowering Treatments for Cardiovascular Disease Prevention in High-Risk Patients. Current Cardiovascular Risk Reports, 2019, 13, 1.	2.0	1
60	Regression of Q waves and clinical outcomes following primary PCI in anterior STEMI. Journal of Electrocardiology, 2019, , .	0.9	2
61	Stimulation of murine P2Y11-like purinoreceptor protects against hypoxia/reoxygenation injury and decreases heart graft rejection lesions. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 780-790.e1.	0.8	9
62	Missed opportunities with underprescription of appropriate secondary prevention treatment at discharge in AMI patients at high risk. The FAST-MI programme. Archives of Cardiovascular Diseases Supplements, 2019, 11, 121-122.	0.0	0
63	Optimizing DAPT Duration in High-RiskÂPatients After CoronaryÂStentÂlmplantation. Journal of the American College of Cardiology, 2019, 73, 755-757.	2.8	4
64	Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. New England Journal of Medicine, 2019, 381, 2497-2505.	27.0	1,696
65	In-hospital outcomes and 5-year mortality following an acute myocardial infarction in patients with a history of cancer: Results from the French registry on Acute ST-elevation or non-ST-elevation myocardial infarction (FAST-MI) 2005 cohort. Archives of Cardiovascular Diseases, 2019, 112, 657-669.	1.6	10
66	Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: The FAST-MI 2010 registry. European Journal of Preventive Cardiology, 2019, 26, 411-419.	1.8	13
67	Dual Antiplatelet Therapy Combining Aspirin and Ticagrelor for Intracranial Stenting Procedures: A Retrospective Single Center Study of 154 Consecutive Patients With Unruptured Aneurysms. Neurosurgery, 2019, 84, 77-83.	1.1	41
68	Three case reports of involuntary muscular movements as adverse reactions to sacubitril/valsartan. British Journal of Clinical Pharmacology, 2018, 84, 1072-1074.	2.4	6
69	Temporal trends in clinical characteristics and management according to sex in patients with cardiogenic shock after acute myocardial infarction: The FAST-MI programme. Archives of Cardiovascular Diseases, 2018, 111, 555-563.	1.6	22
70	Effect and Safety of Morphine Use in Acute Anterior STâ€Segment Elevation Myocardial Infarction. Journal of the American Heart Association, 2018, 7, .	3.7	45
71	Changes in glomerular filtration rate and outcomes in patients with atrial fibrillation. American Heart Journal, 2018, 198, 39-45.	2.7	31
72	The CRAC cohort model: A computerized low cost registry of interventional cardiology with daily update and long-term follow-up. Revue D'Epidemiologie Et De Sante Publique, 2018, 66, 209-216.	0.5	22

#	Article	IF	CITATIONS
73	Overview of Systematic Reviews and Meta-analyses on Systemic Adverse Events Associated With Intravitreal Anti–Vascular Endothelial Growth Factor Medication Use. JAMA Ophthalmology, 2018, 136, 557.	2.5	48
74	A consensus statement on lipid management after acute coronary syndrome. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 532-543.	1.0	27
75	Benefits of an early management of palpitations. Medicine (United States), 2018, 97, e11466.	1.0	7
76	The best in coronary artery disease management is yet to come. Archives of Cardiovascular Diseases, 2018, 111, 621-624.	1.6	1
77	Patients' adherence to optimal therapeutic, lifestyle and risk factors recommendations after myocardial infarction: Six years follow-up in primary care. PLoS ONE, 2018, 13, e0202986.	2.5	14
78	Incidence and Significance of Spontaneous ST Segment Re-elevation After Reperfused Anterior Acute Myocardial Infarction ― Relationship With Infarct Size, Adverse Remodeling, and Events at 1 Year―. Circulation Journal, 2018, 82, 1379-1386.	1.6	10
79	Stimulation of P2Y11 receptor modulates cardiac fibroblasts secretome toward immunomodulatory and protective roles after Hypoxia/Reoxygenation injury. Journal of Molecular and Cellular Cardiology, 2018, 121, 212-222.	1.9	15
80	Atrial fibrillation, intra-ventricular thrombus, and other anticoagulant indications relationship with adverse outcomes in acute anterior myocardial infarction patients. Journal of Cardiology, 2018, 72, 277-283.	1.9	2
81	Current indications for the intra-aortic balloon pump: The CP-GARO registry. Archives of Cardiovascular Diseases, 2018, 111, 739-748.	1.6	10
82	FOURIER to ODYSSEY: the end of the journey for lipid-lowering therapy trials? Lessons from recent clinical trials with anti-PCSK9 antibodies. EuroIntervention, 2018, 14, 144-146.	3.2	1
83	The Changing Landscape for StrokeÂPrevention in AF. Journal of the American College of Cardiology, 2017, 69, 777-785.	2.8	244
84	The effect of purinergic signaling via the P2Y11 receptor on vascular function in a rat model of acute inflammation. Molecular and Cellular Biochemistry, 2017, 431, 37-44.	3.1	15
85	Prediction of Systemic Septic Embolism in Patients With Left-Sided Infective Endocarditis. Journal of the American College of Cardiology, 2017, 69, 1992-1993.	2.8	1
86	Is there a role for lifestyle changes in cardiovascular prevention? What, when and how?. Atherosclerosis Supplements, 2017, 26, 2-15.	1.2	31
87	Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation. Advances in Therapy, 2017, 34, 1283-1290.	2.9	4
88	PREDICTORS OF INCIDENT ATRIAL FIBRILLATION IN PATIENTS WITH ISCHEMIC STROKE: A NATIONWIDE COHORT STUDY. Journal of the American College of Cardiology, 2017, 69, 328.	2.8	0
89	INCIDENT ATRIAL FIBRILLATION ACCORDING TO GENDER IN PATIENTS WITH ISCHEMIC STROKE: A NATIONWIDE COHORT STUDY. Journal of the American College of Cardiology, 2017, 69, 367.	2.8	O
90	USE OF MODERN SCORES TO EVALUATE INDIVIDUAL RISK/BENEFIT OF PROLONGED DUAL ANTIPLATELET THERAPY MAY MODIFY DUAL ANTI-PLATELET THERAPY DURATION IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION PATIENTS. Journal of the American College of Cardiology, 2017, 69, 1021.	2.8	0

#	Article	IF	Citations
91	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. New England Journal of Medicine, 2017, 376, 1527-1539.	27.0	510
92	Comparison of Outcome of Possible Versus Definite Infective Endocarditis Involving Native Heart Valves. American Journal of Cardiology, 2017, 119, 1854-1861.	1.6	6
93	Revisiting myocardial necrosis biomarkers: assessment of the effect of conditioning therapies on infarct size by kinetic modelling. Scientific Reports, 2017, 7, 10709.	3.3	14
94	Relationship of Preexisting Cardiovascular Comorbidities to Newly Diagnosed Atrial Fibrillation After Ischemic Stroke. Stroke, 2017, 48, 2878-2880.	2.0	12
95	False positive results in preclinical research. Therapie, 2017, 72, 411-413.	1.0	1
96	Prognosis in patients with atrial fibrillation and a presumed "temporary cause―in a community-based cohort study. Clinical Research in Cardiology, 2017, 106, 202-210.	3.3	24
97	Risk of myocardial infarction and death in patients with atrial fibrillation treated with dabigatran or vitamin K antagonists. Thrombosis and Haemostasis, 2016, 116, 1150-1158.	3.4	8
98	Immature human dendritic cells enhance their migration through KCa3.1 channel activation. Cell Calcium, 2016, 59, 198-207.	2.4	16
99	Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA <sub>2</sub> DS <sub>2</sub> -VASc Risk Factor Be Anticoagulated?. Stroke, 2016, 47, 1831-1836.	2.0	59
100	Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor. Chest, 2016, 149, 960-968.	0.8	55
101	Author's reply. Journal of Cardiology, 2016, 67, 393.	1.9	0
102	Long-Term Outcome and Valve Surgery for Infective Endocarditis in the Systematic Analysis of a Community Study. Annals of Thoracic Surgery, 2016, 102, 496-504.	1.3	33
103	Is oral anticoagulation needed in patients with atrial fibrillation and stent implantation at low–moderate risk of stroke?. European Journal of Internal Medicine, 2016, 35, e9-e10.	2.2	2
104	Causes of Death and Influencing Factors in Patients with Atrial Fibrillation. American Journal of Medicine, 2016, 129, 1278-1287.	1.5	139
105	The very high cardiovascular risk in heterozygous familial hypercholesterolemia: Analysis of 734 French patients. Journal of Clinical Lipidology, 2016, 10, 1129-1136.e3.	1.5	19
106	Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. Thrombosis and Haemostasis, 2016, 115, 1056-1063.	3.4	33
107	Evaluation of 5 Prognostic Scores for Prediction of Stroke, Thromboembolic and Coronary Events, All-Cause Mortality, and Major Adverse Cardiac Events in Patients With Atrial Fibrillation and Coronary Stenting. American Journal of Cardiology, 2016, 118, 700-707.	1.6	22
108	Bleeding risk in patients treated with dabigatran or vitamin K antagonist for atrial fibrillation: A meta analysis of adjusted analysis in routine practice settings. International Journal of Cardiology, 2016, 206, 89-92.	1.7	3

#	Article	IF	CITATIONS
109	CHA2DS2-VASc Score forÂPredicting Stroke andÂThromboembolism inÂPatients With AF andÂBiological Valve Prosthesis. Journal of the American College of Cardiology, 2016, 67, 343-344.	2.8	11
110	Pre-PCI angiographic TIMI flow in the culprit coronary artery influences infarct size and microvascular obstruction in STEMI patients. Journal of Cardiology, 2016, 67, 248-253.	1.9	18
111	Antithrombotic management in patients with atrial fibrillation undergoing coronary stent implantation: What is the impact of guideline adherence?. International Journal of Cardiology, 2016, 203, 987-994.	1.7	21
112	Effect of Pre-Hospital Ticagrelor During the FirstÂ24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2016, 9, 646-656.	2.9	31
113	Remote ischemic preconditioning in aortic valve surgery: Results of a randomized controlled study. Journal of Cardiology, 2016, 67, 36-41.	1.9	37
114	Effect of Active Smoking on Comparative Efficacy of Antithrombotic Therapy in Patients With Atrial Fibrillation. Chest, 2015, 148, 491-498.	0.8	9
115	Cyclosporine Protects the Heart During Aortic Valve Surgery. Survey of Anesthesiology, 2015, 59, 163.	0.1	1
116	Influence of cardiovascular risk factors on infarct size and interaction with mechanical ischaemic postconditioning in ST-elevation myocardial infarction. Open Heart, 2015, 2, e000175.	2.3	7
117	Rationale and design of the Cyclosporine to ImpRove Clinical oUtcome in ST-elevation myocardial infarction patients (the CIRCUS trial). American Heart Journal, 2015, 169, 758-766.e6.	2.7	27
118	Prognostic value of CHA <sub>2</sub> DS <sub>2</sub> -VASc score in patients with â€~non-valvular atrial fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project. European Heart Journal, 2015, 36, 1822.2-1830.	2.2	53
119	How to define valvular atrial fibrillation?. Archives of Cardiovascular Diseases, 2015, 108, 530-539.	1.6	86
120	Hypoxia/Reoxygenation Inhibits P2Y11 Receptor Expression and Its Immunosuppressive Activity in Human Dendritic Cells. Journal of Immunology, 2015, 195, 651-660.	0.8	32
121	Remote ischemic conditioning and cardioprotection: a systematic review and meta-analysis of randomized clinical trials. Basic Research in Cardiology, 2015, 110, 11.	5.9	66
122	Dual antiplatelet therapy after acute coronary syndrome: a cardiologist-based optimal decision. Heart, 2015, 101, 832-833.	2.9	0
123	The SAMe-TT2R2 score and quality of anticoagulation in atrial fibrillation: a simple aid to decision-making on who is suitable (or not) for vitamin K antagonists. Europace, 2015, 17, 671-673.	1.7	16
124	Cyclosporine before PCI in Patients with Acute Myocardial Infarction. New England Journal of Medicine, 2015, 373, 1021-1031.	27.0	557
125	Ischaemic postconditioning reduces infarct size: Systematic review and meta-analysis of randomized controlled trials. Archives of Cardiovascular Diseases, 2015, 108, 39-49.	1.6	21
126	Long-term outcome in early survivors of cardiogenic shock at the acute stage of myocardial infarction: a landmark analysis from the French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) Registry. Critical Care, 2014, 18, 516.	5.8	34

#	Article	IF	CITATIONS
127	Cardiovascular Events and Bleeding Risk Associated With Intravitreal Antivascular Endothelial Growth Factor Monoclonal Antibodies. JAMA Ophthalmology, 2014, 132, 1317.	2.5	108
128	The activation of P2Y2 receptors increases MCF-7 breast cancer cells migration through the MEK-ERK1/2 signalling pathway. Carcinogenesis, 2014, 35, 1238-1247.	2.8	71
129	Cardiac fibroblasts protect cardiomyocytes against lethal ischemia–reperfusion injury. Journal of Molecular and Cellular Cardiology, 2014, 68, 56-65.	1.9	62
130	The RIPOST-MI study, assessing remote ischemic perconditioning alone or in combination with local ischemic postconditioning in ST-segment elevation myocardial infarction. Basic Research in Cardiology, 2014, 109, 400.	5.9	107
131	Predictive factors of contrast-induced nephropathy in patients undergoing primary coronary angioplasty. Archives of Cardiovascular Diseases, 2014, 107, 424-432.	1.6	16
132	Efficacy of new oral anticoagulants in patients with atrial fibrillation previously treated with warfarin: A meta-analysis of randomized controlled trials. International Journal of Cardiology, 2014, 173, 122-124.	1.7	2
133	Lack of group X secreted phospholipase A2 increases survival following pandemic H1N1 influenza infection. Virology, 2014, 454-455, 78-92.	2.4	21
134	Cyclosporine Protects the Heart during Aortic Valve Surgery. Anesthesiology, 2014, 121, 232-238.	2.5	53
135	Postconditioning attenuates no-reflow in STEMI patients. Basic Research in Cardiology, 2013, 108, 383.	5.9	81
136	Four-Dimensional Speckle Tracking for Assessing Improvement in Left Ventricular Contractility After Coronary Angioplasty. Ultrasound in Medicine and Biology, 2013, 39, 102-110.	1.5	5
137	Cardioprotection against myocardial reperfusion injury: successes, failures, and perspectives. Canadian Journal of Physiology and Pharmacology, 2013, 91, 657-662.	1.4	10
138	Magnesium orotate elicits acute cardioprotection at reperfusion in isolated and in vivo rat hearts. Canadian Journal of Physiology and Pharmacology, 2013, 91, 108-115.	1.4	10
139	Volatile anaesthetics and cardioprotection – lessons from animal studies. Fundamental and Clinical Pharmacology, 2013, 27, 21-34.	1.9	16
140	Antiplatelet therapy strategies after percutaneous coronary intervention in patients needing oral anticoagulation. Future Cardiology, 2013, 9, 759-762.	1.2	0
141	Regionalization of services improves access to emergency vascular surgical care. Vascular, 2013, 21, 69-74.	0.9	6
142	Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation. Thrombosis and Haemostasis, 2013, 110, 560-568.	3.4	41
143	In Vitro and In Vivo Models of Cerebral Ischemia Show Discrepancy in Therapeutic Effects of M2 Macrophages. PLoS ONE, 2013, 8, e67063.	2.5	43
144	Myocardial microvascular disease and major adverse cardiovascular events in patients with end-stage renal disease: rationale and design of the MICROCARD study. Nephrology Dialysis Transplantation, 2012, 27, 2886-2891.	0.7	10

#	Article	IF	Citations
145	The IDEAL Study: Towards Personalized Drug Treatment of Hypertension. Therapie, 2012, 67, 195-204.	1.0	3
146	Opposite and tissue-specific effects of coenzyme Q2 on mPTP opening and ROS production between heart and liver mitochondria: Role of complex I. Journal of Molecular and Cellular Cardiology, 2012, 52, 1091-1095.	1.9	15
147	Lack of Microsomal Prostaglandin E <sub>2</sub> Synthase-1 in Bone Marrow–Derived Myeloid Cells Impairs Left Ventricular Function and Increases Mortality After Acute Myocardial Infarction. Circulation, 2012, 125, 2904-2913.	1.6	26
148	Comparison of Frequency of Major Adverse Events in Patients With Atrial Fibrillation Receiving Bare-Metal Versus Drug-Eluting Stents in Their Coronary Arteries. American Journal of Cardiology, 2012, 110, 7-12.	1.6	15
149	Late diagnosis of incomplete Cantrell's syndrome on CT scan. Archives of Cardiovascular Diseases, 2011, 104, 208-210.	1.6	2
150	Mesenchymal stem cell conditioned media attenuates in vitro and ex vivo myocardial reperfusion injury. Journal of Heart and Lung Transplantation, 2011, 30, 95-102.	0.6	108
151	Effect of Cyclosporine on Left Ventricular Remodeling After Reperfused Myocardial Infarction. Journal of the American College of Cardiology, 2010, 55, 1200-1205.	2.8	170
152	Cell-based gene therapy modifies matrix remodeling after a myocardial infarction in tissue inhibitor of matrix metalloproteinase-3–deficient mice. Journal of Thoracic and Cardiovascular Surgery, 2009, 137, 471-480.e2.	0.8	23
153	Preventing acute decrease in renal function induced by coronary angiography (PRECORD): a prospective randomized trial. Archives of Cardiovascular Diseases, 2009, 102, 761-767.	1.6	8
154	Mesenchymal stem cells engineered to overexpress stem cell factor improve cardiac function but have malignant potential. Journal of Thoracic and Cardiovascular Surgery, 2008, 136, 1388-1389.	0.8	22
155	Effect of Cyclosporine on Reperfusion Injury in Acute Myocardial Infarction. New England Journal of Medicine, 2008, 359, 473-481.	27.0	1,189
156	Long-Term Benefit of Postconditioning. Circulation, 2008, 117, 1037-1044.	1.6	384
157	Microsomal Prostaglandin E <sub>2</sub> Synthase-1 Deletion Leads to Adverse Left Ventricular Remodeling After Myocardial Infarction. Circulation, 2008, 117, 1701-1710.	1.6	88
158	Activation of câ€kit is necessary for mobilization of reparative bone marrow progenitor cells in response to cardiac injury. FASEB Journal, 2008, 22, 930-940.	0.5	66
159	Post-conditioning Protects From Cardioplegia and Cold Ischemia via Inhibition of Mitochondrial Permeability Transition Pore. Journal of Heart and Lung Transplantation, 2007, 26, 604-609.	0.6	21
160	c-Jun N-terminal Kinase-mediated Stabilization of Microsomal Prostaglandin E2 Synthase-1 mRNA Regulates Delayed Microsomal Prostaglandin E2 Synthase-1 Expression and Prostaglandin E2 Biosynthesis by Cardiomyocytes. Journal of Biological Chemistry, 2006, 281, 16443-16452.	3.4	27
161	Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. Journal of Clinical Investigation, 2006, 116, 1865-1877.	8.2	468
162	Heart cell implantation after myocardial infarction. Coronary Artery Disease, 2005, 16, 85-91.	0.7	7

#	Article	IF	CITATIONS
163	Cell transplantation preserves cardiac function after infarction by infarct stabilization: Augmentation by stem cell factor. Journal of Thoracic and Cardiovascular Surgery, 2005, 130, 1310.e1-1310.e10.	0.8	84
164	Cell Transplantation Improves Ventricular Function After a Myocardial Infarction. Circulation, 2005, 112, 196-104.	1.6	124
165	Cell transplantation for heart disease: The clinical perspective. Evidence-based Cardiovascular Medicine, 2005, 9, 2-7.	0.0	6
166	Current Status of Cellular Therapy for Ischemic Heart Disease. Annals of Thoracic Surgery, 2005, 79, S2238-S2247.	1.3	32
167	Neovascularization derived from cell transplantation in ischemic myocardium. Molecular and Cellular Biochemistry, 2004, 264, 133-142.	3.1	11
168	INVITED COMMENTARY. Annals of Thoracic Surgery, 2004, 78, 1812-1813.	1.3	1
169	Septic shock caused by Mycobacterium tuberculosis in a non-HIV patient. Intensive Care Medicine, 1999, 25, 238-238.	8.2	14
170	Laser guidance system for CT-guided procedures Radiology, 1995, 194, 282-284.	7.3	28